The Science of Investing
EARLY
STAGE
SPECIALTY
EXPERTISE
PIONEERING
INNOVATION
About Astera
Target
Early Stage Cell & Gene Therapy
Astera targets cell and gene therapy companies in their early stage when minimal information is available regarding pre-IND/phase I and pre-revenue assets, capitalizing on our expertise and leveraging our ability to discern the most successful investments in the space.
The Astera investment thesis asserts that the critical requirement for successful investing in early cell and gene therapy public equities is a fundamental understanding of the underlying biology and chemistry, the context of their application, and likelihood of clinical translation.
OBJECTIVE
A private equity approach to public equities, evaluating the science, technology, and operational likelihood of success. Seeking binary outcomes in smaller cap positions with winners outpacing losers at 1.5-3X+ multiple of invested capital.
COMPETITIVE ADVANTAGE
In depth expertise in biotech success criteria including science, medicine, drug development, regulatory, clinical operations, and commercialization which allows an unbiased selection of undervalued early stage biotech equities.
RISK MANAGEMENT
Balance binary outcomes of early stage biotech companies with a few larger established companies entering the cell and gene therapy space to minimize volatility. Opportunistically short companies based on conviction of flawed science.
Who We Are
Astera Bio is a boutique asset management firm founded in 2019 and is 100% woman and employee-owned.
Astera borrows its name from the plant genus of Asteraceae discovered by Ynes Mexia, arguably the most accomplished plant collector of her time who began her botany career in her mid-50s.
Meet Our Team
The best investors invest in what they know; we seek to source the best equities in the space to identify, measure, and rank the risk associated with each potential investment.
Scientifically and medically trained research analyst and portfolio manager.
Chief Investment Officer
Seasoned operating professional who has held various roles within operations, product development and corporate strategy.
Chief Operating Officer
Discover Astera
Beginning with a broad global universe of companies that fall under health care, pharma and biotech, Astera narrows it universe specifically to cell and gene related companies.
